Erratum: Aberrant dna damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer (PLoS ONE (2015) 10:2 (e0117654) DOI: 10.1371/journal.pone.0117654);Aberrant dna damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Stefanou, Dimitra T ^a,b   Bamias, Aristotelis ^b   Episkopou, Hara ^a,c   Kyrtopoulos, Soterios A ^a   Likka, Maria ^b   Kalampokas, Theodore ^b   Photiou, Stylianos ^b   Gavalas, Nikos ^b   Sfikakis, Petros P ^b   Dimopoulos, Meletios A ^b   Souliotis, Vassilis L ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PELVIS EXENTERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; SURVIVAL RATE; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM; SURVIVAL RATE;

EID: 84922643512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0256051     Document Type: Erratum

References (61)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer Statistics. CA Cancer J Clin 64: 9-29. doi: 10.3322/ caac.21208 PMID: 24399786
2. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384: 1376-1388.doi: 10.1016/S0140-6736(13)62146-7 PMID: 24767708
3. Kim A, Ueda Y, Naka T, Enomoto T (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31: 14. doi: 10.1186/1756-9966-31-14 PMID: 22330607
4. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10. PMID: 10883018
5. Ozols RF (2000) Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 27(3 Suppl 7): 47-49. PMID: 10952127
6. Kemp Z, Ledermann J (2013) Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health 5: 45-51. doi: 10.2147/IJWH.S30231 PMID: 23378788
7. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707-713. PMID: 4039603
8. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43. PMID: 11406167
9. Bowden NA (2014) Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Lett 346: 163-171. doi: 10.1016/j.canlet.2014.01.005 PMID: 24462818
10. Deans AJ, West SC (2011) DNA interstrand crosslink repair and cancer. Nat Rev Cancer 11: 467-480. doi: 10.1038/nrc3088 PMID: 21701511
11. Thompson LH, Hinz JM (2009) Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 668: 54-72. doi: 10.1016/j. mrfmmm.2009.02.003 PMID: 19622404
12. Dronkert ML, Kanaar R (2001) Repair of DNA interstrand cross-links. Mutat Res 486: 217-247. PMID: 11516927
13. Mogi S1, Oh DH (2006) Gamma-H2AX formation in response to interstrand crosslinks requires XPF in human cells. DNA Repair (Amst) 5: 731-740. PMID: 16678501
14. Kuo LJ, Yang LX (2008) Gamma-H2AX-a novel biomarker for DNA double-strand breaks. In Vivo 22: 305-309. PMID: 18610740
15. Lagerwerf S, Vrouwe MG, Overmeer RM, Fousteri MI, Mullenders LH (2011) DNA damage response and transcription. DNA Repair (Amst) 10: 743-750. doi: 10.1016/j.dnarep.2011.04.024 PMID: 21622031
16. Karst AM, Drapkin R (2010) Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010: 932371. doi: 10.1155/2010/932371 PMID: 19746182
17. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991. PMID: 16957145
18. Reed E (2006) ERCC1 measurements in clinical oncology. N Engl J Med 355: 1054-1055. PMID: 16957152
19. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, et al. (2009) The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815. doi: 10.1002/ijc.23987 PMID: 19035454
20. Souliotis VL, Dimopoulos MA, Sfikakis PP (2003) Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res 9: 4465-4474. PMID: 14555520
21. Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP (2005) Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol 23: 4381-4389. PMID: 15883412
22. Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, et al. (2007) Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica 92: 1505-1512. PMID: 18024399
23. Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkotzamanidou M, et al. (2012) Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. Br J Clin Pharmacol 74: 842-853. doi: 10.1111/j.1365-2125.2012.04274.x PMID: 22432918
24. Gkotzamanidou M, Sfikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, et al. (2014) Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. Br J Cancer 111: 1293-1304. doi: 10.1038/bjc.2014.410 PMID: 25051404
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Natl Cancer Inst 92: 205-216. PMID: 10655437
26. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, et al. (1993) Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53: 5225-5232. PMID: 8106143
27. Frgala T, Kalous O, Proffitt RT, Reynolds CP (2007) A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 6: 886-897. PMID: 17363483
28. Forchhammer L, Ersson C, Loft S, Möller L, Godschalk RW, et al. (2012) Inter-laboratory variation in DNA damage using a standard comet assay protocol. Mutagenesis 27: 665-672. doi: 10.1093/ mutage/ges032 PMID: 22844078
29. Stellas D, Karameris A, Patsavoudi E (2007) Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 13: 1831-1838. PMID: 17363539
30. Møller P (2006) The alkaline comet assay: towards validation in biomonitoring of DNA damaging exposures. Basic Clin Pharmacol Toxicol 98: 336-345. PMID: 16623855
31. de Feraudy S, Revet I, Bezrookove V, Feeney L, Cleaver JE (2010) A minority of foci or pan-nuclear apoptotic staining of gammaH2AX in the S phase after UV damage contain DNA double-strand breaks. Proc Natl Acad Sci U S A 107: 6870-6875. doi: 10.1073/pnas.1002175107 PMID: 20351298
32. Scarpato R, Castagna S, Aliotta R, Azzarà A, Ghetti F, et al. (2013) Kinetics of nuclear phosphorylation (γ-H2AX) in human lymphocytes treated in vitro with UVB, bleomycin and mitomycin C. Mutagenesis 28: 465-473. doi: 10.1093/mutage/get024 PMID: 23696313
33. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, et al. (2008) Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 76: 19-27. doi: 10.1016/j.bcp.2008.03.025 PMID: 18508035
34. Tompkins JD, Wu X, Her C (2012) MutS homologue hMSH5: role in cisplatin-induced DNA damage response. Mol Cancer 11: 10. doi: 10.1186/1476-4598-11-10 PMID: 22401567
35. Al-Minawi AZ, Lee YF, Håkansson D, Johansson F, Lundin C, et al. (2009) The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by interstrand cross-links. Nucleic Acids Res 37: 6400-6413. doi: 10.1093/nar/gkp705 PMID: 19713438
36. Olive PL, Banáth JP (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1: 23-29. PMID: 17406208
37. Unger FT, Klasen HA, Tchartchian G, de Wilde RL, Witte I (2009) DNA damage induced by cis- and carbo-platin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer 9: 359. doi: 10. 1186/1471-2407-9-359 PMID: 19818145
38. Alberg AJ, Jorgensen TJ, Ruczinski I, Wheless L, Shugart YY, et al. (2013) DNA repair gene variants in relation to overall cancer risk: a population-based study. Carcinogenesis 34: 86-92. doi: 10.1093/ carcin/bgs304 PMID: 23027618
39. Udumudi A, Jaiswal M, Rajeswari N, Desai N, Jain S, et al. (1998) Risk assessment in cervical dysplasia patients by single cell gel electrophoresis assay: a study of DNA damage and repair. Mutat Res 412: 195-205. PMID: 9539974
40. Lieber MR (2010) The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79: 181-211. doi: 10.1146/annurev.biochem.052308.093131 PMID: 20192759
41. Hefferin ML, Tomkinson AE (2005) Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair 4: 639-648. PMID: 15907771
42. Weterings E, Chen DJ (2008) The endless tale of non-homologous end-joining. Cell Res 18: 114-124. doi: 10.1038/cr.2008.3 PMID: 18166980
43. Gospodinov A, Herceg Z (2013) Chromatin structure in double strand break repair. DNA Repair (Amst) 12: 800-810. doi: 10.1016/j.dnarep.2013.07.006 PMID: 23919923
44. Povirk LF (2006) Biochemical mechanisms of chromosomal translocations resulting from DNA double strand breaks. DNA Repair (Amst) 5: 1199-1212. PMID: 16822725
45. Helleday T, Lo J, van Gent DC, Engelward BP (2007) DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6: 923-935. PMID: 17363343
46. Solier S, Sordet O, Kohn KW, Pommier Y (2009) Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 29: 68-82. doi: 10.1128/ MCB.00581-08 PMID: 18955500
47. Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, et al. (2012) Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genomics 5: 47. doi: 10.1186/1755-8794-5-47 PMID: 23078675
48. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, et al. (2013) Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (Suppl 7): vii20-26. PMID: 22997450
49. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4: 2126. doi: 10.1038/ncomms3126 PMID: 23839242
50. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, et al. (2008) Epigenotyping in peripheral blood cell DNA and breast cancer risk: A proof of principle study. PLoS One 3: e2656. doi: 10. 1371/journal.pone.0002656 PMID: 18628976
51. Rotunno M, Hu N, Su H, Wang C, Goldstein AM, et al. (2011) A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma. Cancer Prev Res (Phila) 4: 1599-1608. doi: 10. 1158/1940-6207.CAPR-10-0170 PMID: 21742797
52. Zander T, Hofmann A, Staratschek-Jox A, Classen S, Debey-Pascher S, et al. (2011) Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res 17: 3360-3367. doi: 10. 1158/1078-0432.CCR-10-0533 PMID: 21558400
53. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, et al. (2009) An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 4: e8274. doi: 10.1371/journal. pone.0008274 PMID: 20019873
54. Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, et al. (2011) DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol 29: 1133-1139. doi: 10.1200/JCO.2010.31.3577 PMID: 21343564
55. Marshall KW, Mohr S, Khettabi FE, Nossova N, Chao S, et al. (2010) A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer 126: 1177-1186. doi: 10.1002/ijc.24910 PMID: 19795455
56. Anderson D, Najafzadeh M, Gopalan R, Ghaderi N, Scally AJ, et al. (2014) Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics. FASEB J 28: 4563-4570. doi: 10.1096/fj.14-254748 PMID: 25063845
57. Hoebers FJ, Pluim D, Verheij M, Balm AJ, Bartelink H, et al. (2006) Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 119: 750-756. PMID: 16550603
58. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC (1987) Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A 84: 5024-5028. PMID: 3110781
59. Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, et al. (2011) DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinumbased chemotherapy. J Clin Oncol 29: 4121-4128. doi: 10.1200/JCO.2010.34.3616 PMID: 21947825
60. Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, et al. (2013) Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol 131: 352-356. doi: 10.1016/j.ygyno.2013.08.006 PMID: 23954902
61. Kim JH, Chung HH, Jeong MS, Song MR, Kang KW, et al. (2013) One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles. Int J Nanomedicine 8: 2247-2257. doi: 10.2147/IJN.S45059 PMID: 23818781